ARDS — Aridis Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.01m
- -$0.03m
- $3.09m
Brief: Aridis Receives Agreement From The FDA On Single Confirmatory Phase 3 Study Of Ar-301 And The Clinical Study Design
Brief: Aridis Pharmaceuticals Receives Nasdaq Notice On Late Filing Of Its Form 10-Q
Aridis Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Aridis Pharmaceuticals Inc expected to post a loss of 41 cents a share - Earnings Preview
Brief: Aridis Says On May 3 Co Sent Notice To Serum Stating That As Of May 8, License, Development, Commercialization Agreement Between Co, Serum Would Terminate
Brief: Aridis Pharmaceuticals Receives Nasdaq Notice On Late Filing Of Its Form 10-K
Brief: Aridis Pharmaceuticals Received Notice Of Delisting From Nasdaq
Brief: Aridis Pharmaceuticals Securities Will Be Delisted From Nasdaq
U.S. STOCKS ON THE MOVE-Terns Pharma, Rivian, Intel, Micron
U.S. STOCKS ON THE MOVE-Nikola, Cintas, Seagate
Aridis Pharmaceuticals falls on pausing pneumonia drug study
Brief: Aridis Pharmaceuticals Notified Of Terminated License Agreement With Medimmune
Aridis Pharmaceuticals Inc expected to post a loss of 41 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Moderna, Genie Energy, Merck & Co
U.S. STOCKS ON THE MOVE-Tesla, Rivian, Phathom Pharmaceuticals
U.S. STOCKS ON THE MOVE-Eli Lilly, Mersana, Illumina
Aridis surges as lung infection therapy succeeds in mid-stage trial
Brief: Aridis Meets Primary And Secondary Endpoints In Phase 2A Study Of Ar-501 In Cystic Fibrosis Patients
U.S. STOCKS ON THE MOVE-Foot Locker, Nemaura, Chipotle